A5010229789- Lung Cancer Treatments and Mutations
- Neutropenia and Cancer Infections
- HER2/EGFR in Cancer Research
- Blood disorders and treatments
- Cancer Treatment and Pharmacology
- Antifungal resistance and susceptibility
- Lymphoma Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Chronic Lymphocytic Leukemia Research
- T-cell and Retrovirus Studies
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Synthesis and biological activity
- Cardiac Imaging and Diagnostics
- Hormonal and reproductive studies
- Prostate Cancer Treatment and Research
- Viral-associated cancers and disorders
- Monoclonal and Polyclonal Antibodies Research
- Bladder and Urothelial Cancer Treatments
- Ultrasound in Clinical Applications
- Cancer Genomics and Diagnostics
- Cutaneous lymphoproliferative disorders research
- Cardiovascular Disease and Adiposity
- Advanced Breast Cancer Therapies
- Computational Drug Discovery Methods
Spectrum Pharmaceuticals (United States)
2015-2024
Manipal Academy of Higher Education
2018-2022
West Cancer Center
2019
CHA Bundang Medical Center
2019
Los Angeles Medical Center
2019
St. Vincent's HealthCare
2019
University of Minnesota
2019
Marin Endocrine Care and Research
2017
Washington University in St. Louis
2017
The University of Texas Health Science Center at San Antonio
2017
Peripheral T-cell lymphomas (PTCLs) represent a diverse group of non-Hodgkin with poor prognosis and no accepted standard care for patients relapsed or refractory disease. This study evaluated the efficacy tolerability belinostat, novel histone deacetylase inhibitor, as single agent in PTCL.Patients confirmed PTCL who experienced progression after ≥ one prior therapy received belinostat 1,000 mg/m(2) daily 30-minute infusions on days 1 to 5 every 21 days. Central assessment response used...
Insertion mutations in Erb-b2 receptor tyrosine kinase 2 gene (ERBB2 or HER2) exon 20 occur 2%-5% of non-small-cell lung cancers (NSCLCs) and function as an oncogenic driver. Poziotinib, a inhibitor, was evaluated previously treated patients with NSCLC HER2 insertions.ZENITH20, multicenter, multicohort, open-label phase II study, poziotinib advanced metastatic NSCLC. In cohort 2, received (16 mg) once daily. The primary end point objective response rate by independent review committee...
Summary Belinostat is a pan‐histone deacetylase inhibitor with antitumour and anti‐angiogenic properties. An open label, multicentre study was conducted in patients peripheral T‐cell lymphoma ( PTCL ) or cutaneous CTCL who failed ≥1 prior systemic therapy were treated belinostat (1000 mg/m 2 intravenously ×5 d of 21‐d cycle). The primary endpoint objective response rate ORR ). Patients n = 24) had received median three therapies (range 1–9) 40% stage IV disease. 29) one skin‐directed 0–4)...
9514 Background: Treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 mutations is an unmet medical need. Poziotinib a potent tyrosine kinase inhibitor (TKI) and HER2 insertion mutants. We evaluated the efficacy safety poziotinib in previously treated NSCLC patients independent cohort multi-cohort, multi-center Phase 2 study ( ZENITH20-1). Methods: ZENITH20-1 enrolled pts advanced identified on local tissue testing who had received at least one prior line therapy. (16 mg) was...
Abstract Background Belinostat is a histone deacetylase inhibitor approved for relapsed refractory peripheral T-cell lymphoma (PTCL). The primary objective of this study was to determine the maximum tolerated dose (MTD) belinostat combined with CHOP (Bel-CHOP). Secondary objectives included safety/tolerability, overall response rate (ORR), and pharmacokinetics (PK). Methods Patients were ≥ 18 years histologically confirmed, previously untreated PTCL. received (1000 mg/m 2 once daily) +...
Although prostate cancer specific mortality is decreasing, there little effect on overall in this population, suggesting the possibility of an increased risk death from nonprostate related causes. Androgen deprivation therapy could adversely affect cardiovascular health. We investigated changes lipid and glucose during androgen therapy.We performed exploratory analysis pooled data 3 prospective clinical trials aimed at achieving medical castration by comparing gonadotropin releasing hormone...
We have described the synthesis of new 1,2,4-triazoles and evaluated their antimicrobial profile. Antitubercular activity was determined in triplicate using Lowenstein-Jensen medium. A loopful Mycobacterium tuberculosis suspension inoculated on surface each media containing test compounds (100, 10 or 1 microg mL(-1)). To evaluate in-vitro antibacterial activity, (50, 5 0.5 microg) were against B. subtilis, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus typhi by disc...
Abstract Purpose: Most stage IIA colon cancer patients receive no adjuvant therapy despite an estimated 15% risk of disease-related death within 5 years resection. Prognostication disease outcome would benefit the clinician by categorizing with risk. The abundance signal transduction proteins p66 Shc and tyrosine-phosphorylated (PY)-Shc in tumor cells is a prognostic indicator breast cancer, suggesting that analysis may provide information cancer. Experimental Design: Immunohistochemical...
Autologous stem cell transplantation (ASCT) after high-dose melphalan conditioning is considered a standard of care procedure for patients with multiple myeloma (MM). Current formulations (eg, Alkeran Injection [melphalan hydrochloride]; GlaxoSmithKline, Research Triangle Park, NC, USA) have marginal solubility and limited chemical stability upon reconstitution. requires the use propylene glycol as co-solvent, which itself has been reported to cause such complications metabolic/renal...
A study of vincristine sulfate (VCR) liposome injection (VSLI) was conducted in patients with advanced, relapsed, or refractory, Philadelphia chromosome-negative acute lymphoblastic/lymphocytic leukemia (ALL). retrospective subgroup analysis the results performed to evaluate safety and efficacy VSLI adolescent young adult (AYA) patients.Of 65 treated pivotal Phase 2 Study HBS407 (NCT00495079), 44 were aged ≤39 years (median 27 [range 19-39] years) included this analysis. Patients received...
Eflapegrastim, a novel, long-acting recombinant human granulocyte-colony stimulating factor (rhG-CSF), consists of rhG-CSF analog conjugated to IgG4 Fc fragment via short polyethylene glycol linker. Preclinical and phase I II pharmacodynamic pharmacokinetic data showed increased potency for neutrophil counts eflapegrastim versus pegfilgrastim. This open-label III trial compared the efficacy safety with pegfilgrastim reducing risk chemotherapy-induced neutropenia.Patients early-stage breast...
Abstract Eflapegrastim (Rolontis ® ) is a novel, long‐acting hematopoietic growth factor consisting of recombinant human granulocyte‐colony stimulating (rhG‐CSF) analog conjugated to IgG4 Fc fragment via short polyethylene glycol linker. We report results from second pivotal, randomized, open‐label, Phase 3 study comparing the efficacy and safety eflapegrastim pegfilgrastim for reducing risk chemotherapy‐induced neutropenia. Patients with Stage I IIIA early‐stage breast cancer (ESBC) were...